Search Result

Results for "

JAK2 kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	JAK (71) Ack1 (1) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (22) Aurora Kinase (7) Autophagy (5) Bcr-Abl (5) Btk (1) c-Myc (1) Cannabinoid Receptor (1) Caspase (1) CDK (2) EGFR (5) Epigenetic Reader Domain (1) ERK (2) Ferroptosis (1) FGFR (1) FLT3 (7) Glutathione Peroxidase (1) GSK-3 (3) HDAC (1) IFNAR (2) Influenza Virus (1) Interleukin Related (9) IRAK (1) Isotope-Labeled Compounds (4) LRRK2 (1) MEK (2) Microtubule/Tubulin (1) Mitosis (2) mTOR (1) NADH Dehydrogenase (1) Parasite (2) PARP (1) PDGFR (1) Polo-like Kinase (PLK) (1) Protease Activated Receptor (PAR) (1) Reactive Oxygen Species (ROS) (1) Reference Standards (9) RET (3) ROCK (1) ROS Kinase (1) Src (1) STAT (18) Syk (10) Thrombopoietin Receptor (2) TNF Receptor (1) Trk Receptor (1) VEGFR (1) Virus Protease (2)
By Research Areas:	Cancer (53) Cardiovascular Disease (4) Infection (3) Inflammation/Immunology (35) Metabolic Disease (1) Neurological Disease (1)

By Targets:

JAK (71)

Ack1 (1)

Anaplastic lymphoma kinase (ALK) (1)

Apoptosis (22)

Aurora Kinase (7)

Autophagy (5)

Bcr-Abl (5)

Btk (1)

c-Myc (1)

Cannabinoid Receptor (1)

Caspase (1)

CDK (2)

EGFR (5)

Epigenetic Reader Domain (1)

ERK (2)

Ferroptosis (1)

FGFR (1)

FLT3 (7)

Glutathione Peroxidase (1)

GSK-3 (3)

HDAC (1)

IFNAR (2)

Influenza Virus (1)

Interleukin Related (9)

IRAK (1)

Isotope-Labeled Compounds (4)

LRRK2 (1)

MEK (2)

Microtubule/Tubulin (1)

Mitosis (2)

mTOR (1)

NADH Dehydrogenase (1)

Parasite (2)

PARP (1)

PDGFR (1)

Polo-like Kinase (PLK) (1)

Protease Activated Receptor (PAR) (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (9)

RET (3)

ROCK (1)

ROS Kinase (1)

Src (1)

STAT (18)

Syk (10)

Thrombopoietin Receptor (2)

TNF Receptor (1)

Trk Receptor (1)

VEGFR (1)

Virus Protease (2)

By Research Areas:

Cancer (53)

Cardiovascular Disease (4)

Infection (3)

Inflammation/Immunology (35)

Metabolic Disease (1)

Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: JAK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19569

Upadacitinib 25+ Cited Publications ABT-494	JAK	Inflammation/Immunology
Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research .

HY-10409

Fedratinib 50+ Cited Publications TG-101348; SAR 302503	JAK Apoptosis	Cancer
Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active *JAK2* inhibitor with IC₅₀s of 3 nM for both *JAK2* and **JAK2V617F kinase*. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis* and has the potential for myeloproliferative disorders research .

HY-100754

Ritlecitinib 5+ Cited Publications PF-06651600	JAK Interleukin Related STAT	Inflammation/Immunology
Ritlecitinib (PF-06651600) is a highly selective, orally active, irreversible covalent *JAK3* inhibitor (IC₅₀=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC₅₀ >10 μ M). Ritlecitinib rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) .

HY-12000

AG490 Maximum Cited Publications 165 Publications Verification Tyrphostin AG490; Tyrphostin B42	EGFR STAT JAK Autophagy	Cancer
AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and *JAK2/3*.

HY-14435

Pyridone 6 10+ Cited Publications	JAK	Cancer
Pyridone 6 is a *pan-JAK* inhibitor, which potently inhibits the JAK kinase family, with IC₅₀s of 1 nM for *JAK2* and TYK2, 5 nM for *JAK3, and 15 nM for JAK1, while displaying significantly weaker affinities (130 nM to >10 mM) for other protein tyrosine kinases*.

HY-112708

Brepocitinib 3 Publications Verification PF-06700841	JAK	Inflammation/Immunology
Brepocitinib (PF-06700841) is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC₅₀s of 17 nM and 23 nM, respectively. Brepocitinib also inhibits *JAK2* and *JAK3* with IC₅₀s of 77 nM and 6.49 μM, respectively .

HY-50867

Lestaurtinib 4 Publications Verification CEP-701; KT-5555	JAK FLT3 Trk Receptor Apoptosis STAT	Cancer
Lestaurtinib (CEP-701) is an orally active and selective RPTKs (receptor protein tyrosine kinase) inhibitor, competitively inhibits ATP binding to the TrkA/B/C domain. Lestaurtinib inhibits RPTKs phosphorylation, with IC₅₀s of 2, 25 and 0.9 nM for FLT3, TrkA and *JAK2, respectively. Lestaurtinib induces apoptosis* and cycle arrest, also can inhibit growth of tumor .

HY-50514

AT9283 5+ Cited Publications	JAK Aurora Kinase Bcr-Abl FLT3 Apoptosis Autophagy	Cancer
AT9283 is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, *JAK2/3, Abl (T315I)* and Flt3 (IC₅₀s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo .

HY-103018

Gusacitinib 1 Publications Verification ASN-002	JAK Syk	Inflammation/Immunology Cancer
Gusacitinib (ASN-002) is an orally active dual *SYK/JAK* kinase inhibitor with IC₅₀ values of 5, 46, 4, 11 and 8 nM for SYK, *JAK1, JAK2, JAK3* and TYK2, respectively. Gusacitinib rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma .

HY-10409A

Fedratinib hydrochloride hydrate 50+ Cited Publications TG-101348 hydrochloride hydrate; SAR 302503 hydrochloride hydrate	JAK Apoptosis	Cancer
Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active *JAK2* inhibitor with IC₅₀s of 3 nM for both *JAK2* and **JAK2V617F kinase*. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis* and has the potential for myeloproliferative disorders research .

HY-10411

AZ960 1 Publications Verification	JAK Apoptosis Parasite Virus Protease	Cancer
AZ960 is a potent and specific inhibitor of the *JAK2* kinase with a K_i of 0.45 nM.

HY-13775

XL019 5 Publications Verification	JAK Apoptosis	Cancer
XL019?is a potent, orally active, and selective *JAK2* inhibitor, with IC₅₀s of 2.2, 134.3, and 214.2 nM for JAK2, JAK1 and JAK3, respectively. XL019 shows 50-fold or greater selectivity for JAK2, versus a panel of over 100 serine/threonine and tyrosine kinases, including other members of the JAK family. XL019 potently inhibits STAT3 and STAT5 phosphorylation in cells harboring either JAK2V617F or wild-type JAK2 .

HY-P10373

pJAK2(1001-1013)	JAK IFNAR Interleukin Related	Infection Inflammation/Immunology
pJAK2(1001-1013) is a cell-penetrating peptide that corresponds to the activation loop of JAK2 tyrosine kinase and functions as a SOCS1/3antagonist. pJAK2 (1001-1013) blocks SOCS1-mediated negative regulation of immune function, and enhances the biological activity of cytokines such as IFNγ and IL6. pJAK2(1001-1013) inhibits the replication of a broad range of viruses and exerts dose-dependent protective efficacy against lethal viral infections. pJAK2(1001-1013) can be used for the study of immune regulation and infection .

HY-145551

Atinvicitinib	JAK Interleukin Related	Inflammation/Immunology
Atinvicitinib is an orally active and selective JAK1 inhibitor. Atinvicitinib blocks signaling of JAK1-dependent pruritogenic and pro-inflammatory cytokines, including those in the IL-31, IL-4, and IL-13 pathways. Atinvicitinib can be used for the researches of pruritus associated with allergic dermatitis and canine atopic dermatitis .

HY-15504A

RGB-286638 free base 3 Publications Verification	CDK GSK-3 MEK JAK	Cancer
RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀s of 3, 5, 50, and 54 nM.

HY-15480

NSC 42834 3 Publications Verification JAK2 Inhibitor V; Z3	JAK	Cancer
NSC 42834 (JAK2 Inhibitor V), a novel specific inhibitor of *Jak2, inhibits Jak2-V617F* and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity.

HY-19569R

Upadacitinib (Standard) 1 Publications Verification ABT-494 (Standard)	Reference Standards JAK	Inflammation/Immunology
Upadacitinib (Standard) is the analytical standard of Upadacitinib. This product is intended for research and analytical applications. Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research .

HY-15504

RGB-286638 3 Publications Verification	CDK GSK-3 MEK JAK	Cancer
RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀s of 3, 5, 50, and 54 nM.

HY-100754C

Ritlecitinib tosylate 5+ Cited Publications PF-06651600 tosylate	JAK Interleukin Related STAT	Inflammation/Immunology
Ritlecitinib (PF-06651600) tosylate is a highly selective, orally active, irreversible covalent *JAK3* inhibitor (IC₅₀=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC₅₀ >10 μ M). Ritlecitinib tosylate rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib tosylate can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE) .

HY-112708A

Brepocitinib P-Tosylate 3 Publications Verification PF-06700841 P-Tosylate	JAK	Inflammation/Immunology
Brepocitinib (PF-06700841) P-Tosylate is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC₅₀s of 17 nM and 23 nM, respectively. Brepocitinib P-Tosylate also inhibits *JAK2* and *JAK3* with IC₅₀s of 77 nM and 6.49 μM, respectively .

HY-18009

(Z)-LFM-A13 3 Publications Verification	Btk Polo-like Kinase (PLK) JAK	Cancer
LFM-A13 is a potent BTK, *JAK2, PLK* inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC₅₀s of 2.5 μM, 10 μM and 61 μM; LFM-A13 shows no effects on JAK1 and JAK3, Src family kinase HCK, EGFR and IRK.

HY-109082

Cevidoplenib SKI-O-703	Syk	Inflammation/Immunology
Cevidoplenib (SKI-O-703) is an orally available inhibitor of *spleen tyrosine kinase* (Syk)*, with potential anti-inflammatory and immunomodulating activities. Cevidoplenib is also the mesylate form of SKI-O-592. Cevidoplenib and SKI-O-592 inhibits BCR-mediated survival, proliferation, and differentiation of B cells. And SKI-O-592 potently inhibits multiple kinases* with IC₅₀s of 6.2 nM (Syk), 1.859 μM (Jak2), 5.807 μM (Jak3), 0.412 μM (RET), 0.687 μM (KOR), 1.783 μM (FLT3), 16.96 μM (FGFR1), 5.662 μM (FGFR3), and 0.709 μM (Pyk2), respectively .

HY-169326S

JAK2-IN-11	Isotope-Labeled Compounds JAK	Cancer
JAK2-IN-11 (Example 6) is a *JAK2* kinase inhibitor with IC₅₀ ≤10 nM against JH2 BIND WT/V617F. JAK2-IN-11 has antitumor activity .

HY-113787

(R)-9b	Ack1 JAK	Cancer
(R)-9b is a potent inhibitor of ACK1 tyrosine kinase (IC₅₀=56 nM) with anticancer activity. (R)-9b exhibits selectivity for ACK1 but has inhibitory effects on JAK family kinases *JAK2* and Tyk2. (R)-9b can be used in the study of hormone-regulated cancers such as prostate and breast cancer .

HY-126242S

Tyk2-IN-7	JAK IFNAR Interleukin Related	Inflammation/Immunology
Tyk2-IN-7 is an orally active TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC₅₀ and K_i.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits *TYK2/JAK1/JAK2* kinase domain. Tyk2-IN-7 can inhibit the IL-23 and IFN-α signaling pathways. Tyk2-IN-7 is commonly used in the study of inflammatory conditions such as colitis .

HY-W722277A

LCC-12 formate	Interleukin Related NADH Dehydrogenase TNF Receptor JAK STAT IRAK	Inflammation/Immunology
LCC-12 (formate) is a copper (II) chelator and a derivative of the biguanide metformin (HY-B0627). LCC-12 (formate) reduces its hydrogen peroxide-dependent oxidation of NADH to NAD+. LCC-12 (formate) reduces IL-1β, IL-2, IL-6, IL-8, and TNF-α levels, as well as *JAK2, STAT2, and IL-1 receptor-associated kinase* 4 (IRAK4) levels in primary human cytokine-activated monocyte-derived macrophages (MDMs). LCC-12 (formate) reduces the number of CD80+ and CD86+ cytokine-activated MDMs. LCC-12 LCC-12 (formate) improves survival in a mouse model of sepsis induced by LPS or cecal ligation and puncture .

HY-164393

ON044580	JAK Bcr-Abl Apoptosis	Cancer
ON044580, an α-benzoyl styryl benzyl sulfide, is a potent and non-ATP-competitive *JAK2* kinase inhibitor with IC₅₀s of 1.23 μM, 1.09 μM for WT and V617F mutant JAK2, respectively. ON044580 inhibits the JAK2 kinase activity either by binding to the STAT-5 binding domain of JAK2 or by binding to an allosteric site. ON044580 exerts its antiproliferative effect in JAK2 ^V617F-positive leukemic cells. ON044580 effectively induces apoptosis of Imatinib (HY-15463)-resistant chronic myelogenous leukemia (CML) cells. ON044580 also inhibits both WT and T315I mutant forms of the BCR-ABL kinase. ON044580 has the potential for myeloproliferative disorders typified by aberrant JAK/STAT signaling .

HY-124858

SC99	STAT JAK Apoptosis	Cardiovascular Disease Cancer
SC99 is an orally active, selective STAT3 inhibitor targeting JAK2-STAT3 pathway. SC99 docks into the ATP-binding pocket of JAK2. SC99 inhibits phosphorylation of JAK2 and STAT3 with no effects on the other kinases associated with STAT3 signaling. SC99 inhibits platelet activation, aggregation and displays potent anti-myeloma, anti-thrombotic activities .

HY-149007

STAT3-IN-11 1 Publications Verification	STAT Apoptosis	Cancer
STAT3-IN-11 (7a) is a selective STAT3 inhibitor that inhibits the phosphorylation of STAT3 at site pTyr705. STAT3-IN-11 inhibits the phosphorylation of downstream genes (Survivin and Mcl-1) without affecting its upstream tyrosine kinases (Src and JAK2) levels and p-STAT1 expression. STAT3-IN-11 can induce cancer cell apoptosis, which is potential for the discovery of effective STAT3 inhibitors and antitumor agents against cancers .

HY-W727879

Upadacitinib-15N,d2 1 Publications Verification ABT-494-¹⁵N,d₂	Isotope-Labeled Compounds	Others
Upadacitinib- ¹⁵N,d₂ (ABT-494- ¹⁵N,d₂) is the deuterium-labeled Upadacitinib (HY-19569). Upadacitinib- ¹⁵N,d₂ (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib- ¹⁵N,d₂ (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib- ¹⁵N,d₂ (ABT-494) can be used for several autoimmune disorders research .

HY-12736A

GSK143 dihydrochloride 1 Publications Verification	Syk ERK	Inflammation/Immunology Cancer
GSK143 dihydrochloride is an orally active and highly selective spleen tyrosine kinase (SYK) inhibitor with a pIC₅₀ of 7.5. GSK143 dihydrochloride inhibits phosphorylated Erk (pErk: pIC₅₀=7.1) . GSK143 dihydrochloride reduces inflammation and prevents recruitment of immune cells in the intestinal muscularis in mice .

HY-P1590

*Tyrosine Protein Kinase* JAK 2 (Phospho-Tyr8, 9)**	JAK	Inflammation/Immunology Cancer
Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide corresponding to amino acids 475 to 491 of mouse JAK2.

HY-100849

JAK 3i	JAK	Inflammation/Immunology
JAK3i is a highly selective *JAK3* inhibitor (IC₅₀: 0.43 nM). JAK3i forms a covalent bond with a cysteine in JAK3, but not the closely related kinase domains in JAK1, JAK2, or TYK2. JAK3i abolishes IL-2-driven T-cell proliferation in vivo and has the potential for autoimmune disease research .

HY-112809

GSK2646264	Syk Src LRRK2 GSK-3 JAK VEGFR Aurora Kinase	Inflammation/Immunology
GSK2646264 (Compound 44) is a potent and selective *spleen tyrosine kinase* (SYK) inhibitor with a pIC₅₀** of 7.1. GSK2646264 also inhibits other kinases with pIC₅₀ values of 5.4, 5.4, 5.3, 5, 4.5, <4.6 and <4.3 against LCK, LRRK2, GSK3β, *JAK2, VEGFR2, Aurora B* and Aurora A, respectively. GSK2646264 is penetrable into the epidermis and dermis of the skin .

HY-19569A

Upadacitinib tartrate tetrahydrate ABT-494 tartrate tetrahydrate	JAK	Inflammation/Immunology
Upadacitinib (ABT-494) tartrate tetrahydrate is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib tartrate tetrahydrate displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib tartrate tetrahydrate can be used for several autoimmune disorders research .

HY-145029

SYK/JAK-IN-1	Syk JAK	Cancer
SYK/JAK-IN-1 is a dual *Syk/Jak2* kinase inhibitor. SYK/JAK-IN-1 is applicable to cancer-related research .

HY-156423

Tubulin/JAK2-IN-1	Microtubule/Tubulin JAK	Cancer
Tubulin/JAK2-IN-1 (compound 7g) is a dual inhibitor of Janus kinase 2 (JAK2) and microtubule. Tubulin/JAK2-IN-1 has potent antiproliferative activity against the cancer cells .

HY-107594

Benzene hexabromide 1 Publications Verification	JAK	Cancer
Benzene hexabromide, a bromohydrocarbon, is a potent inhibitor of *JAK2* tyrosine kinase autophosphorylation.

HY-10409R

Fedratinib (Standard) TG-101348 (Standard); SAR 302503 (Standard)	Reference Standards JAK Apoptosis	Cancer
Fedratinib (Standard) is the analytical standard of Fedratinib. This product is intended for research and analytical applications. Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .

HY-177131

Soficitinib	JAK	Inflammation/Immunology
Soficitinib (Compound 20) is a selective tyrosine kinase 2 (TYK2) and Janus kinase 2 (JAK2) inhibitor, with IC₅₀ values of 0.5 nM and 1.2 nM, respectively. Soficitinib shows promise for research into autoimmune diseases (such as psoriasis, rheumatoid arthritis) and inflammatory diseases .

HY-16449

SB1578 CT-1578	JAK FLT3	Inflammation/Immunology
SB1578 (CT-1578) is a selective *JAK2* and FLT3 inhibitor with an IC₅₀ of 46 nM and 60 nM, respectively. SB1578 exhibits high selectivity for other kinase targets. SB1578 can be used for the study of non-oncology indication rheumatoid arthritis .

HY-P1790

Axltide	JAK	Metabolic Disease
Axltide is based on the mouse Insulin receptor substrate 1 (amino acid 979-989). Axltide is a substrate for Axl, DDR2, Mst1, and JAK2 kinases .

HY-164454

AJI-100	Aurora Kinase STAT JAK Mitosis	Inflammation/Immunology
AJI-100 is a dual-target inhibitor of *Aurora kinase* A and JAK2 with IC₅₀ values of 12.7 nM and 18.5 nM, respectively. AJI-100 directly blocks Aurora kinase A to inhibit T cell mitosis and cell polarity, and inhibits JAK2 activation to inhibit STAT3** phosphorylation, thereby reducing the differentiation of TH1 and TH17 cells. AJI-100 can be used in studies on regulating immune responses and preventing graft-versus-host disease (GVHD) .

HY-151259

TK4b	JAK	Cancer
TK4b is a dual JAK2/3 inhibitor with human JAK2 and JAK3 IC₅₀s of 19.40 nM and 18.42 nM, respectively. TK4b can be used for the research of leukemia and myelofibrosis .

HY-10057

AT9283 hydrochloride	Aurora Kinase	Cancer
AT9283 hydrochloride is a multi-targeted kinase inhibitor with anti-tumor activity. AT9283 hydrochloride has been found to effectively inhibit Aurora A and Aurora B kinases, thereby affecting cell proliferation and survival. AT9283 hydrochloride can also inhibit several other kinases, including JAK2 and Abl (T315I) .

HY-12736

GSK143	Syk ERK	Inflammation/Immunology Cancer
GSK143 is an orally active and highly selective spleen tyrosine kinase (SYK) inhibitor with a pIC₅₀ of 7.5. GSK143 inhibits phosphorylated Erk (pErk: pIC₅₀=7.1) . GSK143 reduces inflammation and prevents recruitment of immune cells in the intestinal muscularis in mice .

HY-178448

EGFR-IN-178	EGFR JAK Ferroptosis Apoptosis Reactive Oxygen Species (ROS) Cannabinoid Receptor Glutathione Peroxidase Caspase	Inflammation/Immunology Cancer
EGFR-IN-178 is an orally active EGFR mutant inhibitor, exhibits highly selective inhibitory activity against mutants of the EGFR enzyme, including Del19 (IC₅₀ = 3.4 nM), L858R/T790 M (IC₅₀ = 2.9 nM), and Del19/T790 M (IC₅₀ = 2.5 nM). EGFR-IN-178 has good activity against *JAK2* (IC₅₀ = 55.6 nM) and *JAK3* (IC₅₀ = 46.1 nM) kinases. EGFR-IN-178 can increase cellular lipid oxide MDA, meanwhile decrease GSH content, causing ferroptosis in cancer cells. EGFR-IN-178 promotes apoptosis by increasing cleaved caspase-3 expression. EGFR-IN-178 can inhibit the phosphorylation of EGFR protein and decrease the active form p-JAK2 for *JAK2, induce an increase in intracellular ROS*. EGFR-IN-178 can be used for the study of non-small cell lung cancer (NSCLC) .

HY-107459

(E/Z)-AG490 1 Publications Verification (E/Z)-Tyrphostin AG490; (E/Z)-Tyrphostin B42	EGFR STAT JAK	Cancer
(E/Z)-AG490 ((E/Z)-Tyrphostin AG490) is a racemic compound of (E)-AG490 and (Z)-AG490 isomers. (E)-AG490 (HY-12000) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and *JAK2/3*.

HY-14435R

Pyridone 6 (Standard)	JAK Reference Standards	Cancer
Pyridone 6 (Standard) is the analytical standard of Pyridone 6. This product is intended for research and analytical applications. Pyridone 6 is a pan-JAK inhibitor, which potently inhibits the JAK kinase family, with IC50s of 1 nM for JAK2 and TYK2, 5 nM for JAK3, and 15 nM for JAK1, while displaying significantly weaker affinities (130 nM to >10 mM) for other protein tyrosine kinases.

HY-10058

AT9283 lactic acid	JAK Aurora Kinase Bcr-Abl FLT3 Apoptosis Autophagy	Cancer
AT9283 lactic acid is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, *JAK2/3, Abl (T315I)* and Flt3 (IC₅₀s ranging from 1 to 30 nM). AT9283 lactic acid inhibits growth and survival of multiple solid tumors in vitro and in vivo .

Cat. No.	Product Name

HY-L008

JAK/STAT Compound Library

709 compounds

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID).

MCE provides 709 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.

Cat. No.	Product Name	Target	Research Area

HY-P10373

pJAK2(1001-1013)	JAK IFNAR Interleukin Related	Infection Inflammation/Immunology
pJAK2(1001-1013) is a cell-penetrating peptide that corresponds to the activation loop of JAK2 tyrosine kinase and functions as a SOCS1/3antagonist. pJAK2 (1001-1013) blocks SOCS1-mediated negative regulation of immune function, and enhances the biological activity of cytokines such as IFNγ and IL6. pJAK2(1001-1013) inhibits the replication of a broad range of viruses and exerts dose-dependent protective efficacy against lethal viral infections. pJAK2(1001-1013) can be used for the study of immune regulation and infection .

HY-P1590

*Tyrosine Protein Kinase* JAK 2 (Phospho-Tyr8, 9)**	JAK	Inflammation/Immunology Cancer
Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide corresponding to amino acids 475 to 491 of mouse JAK2.

HY-P1790

Axltide	JAK	Metabolic Disease
Axltide is based on the mouse Insulin receptor substrate 1 (amino acid 979-989). Axltide is a substrate for Axl, DDR2, Mst1, and JAK2 kinases .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N14094

Tubulosine	Structural Classification Alkaloids Other Alkaloids Rubiaceae Plants Pogonopus tubulosus (A.Rich. ex DC.) K.Schum. Source Classification	JAK Apoptosis Autophagy
Tubulosine is an alkaloid. Tubulosine can be isolated from Pogonopus tubulosus (DC.) Schumann. Tubulosine is an ATP-competitive, selective *JAK3* inhibitor with an IC₅₀ value of 9.9 nM. Tubulosine also inhibits the kinase activities of other JAK family members, the extent of inhibition is less than that of JAK3, with IC₅₀ values of 69.5, 84.9 and 76.3 nM for JAK1, JAK2 and TYK2, respectively. Tubulosine selectively inhibits JAK3 signalling by binding to the ATP-binding site of the kinase of JAK3. Tubulosine induces apoptotic and necrotic/autophagic cell death. Tubulosine inhibits the process of peptide chain elongation by eukaryotic polysomes by, specifically preventing the elongation-factor-2-dependent step of translocation. Tubulosine exhibits anticancer activity in breast cancer cells .

Species:	Human (9)
Tag:	His (7) Strep (1) Tag Free (1) Avi (3) GST (4)
Source:	sf9 insect cells (1) Sf9 insect cells (6) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P701102

	*Janus kinase* 2/JAK2 Protein, Human (381a.a, His)** 1 Publications Verification JAK 2; JAK-2; JAK2; JAK2_HUMAN; Janus Activating kinase 2; Janus kinase 2 (a protein tyrosine kinase); Janus kinase 2; JTK 10; JTK10; kinase JAK2; OTTHUMP00000043260; THCYT3; Tyrosine protein kinase JAK2; Tyrosine-protein kinase JAK2	Human	E. coli
	Janus kinase 2/JAK2 Protein, Human is a recombinant human JAK2 expressed in E. coli with a His tag at the N-terminus. JAK2 is a non-receptor tyrosine kinase.

HY-P704597

	*Janus kinase* 2/JAK2 Protein, Human (Biotinylated, sf9, Avi)** JAK2; Janus kinase 2; tyrosine-protein kinase JAK2; JTK10; JAK-2; Janus kinase 2 (a protein tyrosine kinase); THCYT3	Human	Sf9 insect cells
	The Janus kinase 2 (JAK2) protein is a critical non-receptor tyrosine kinase that drives important cellular processes affecting growth, development, differentiation, and histone modifications. JAK2 plays a role in innate and adaptive immunity, interacting with receptors such as growth hormone, erythropoietin, and interleukins. Janus kinase 2/JAK2 Protein, Human (Biotinylated, sf9) is the recombinant human-derived Janus kinase 2/JAK2 protein, expressed by Sf9 insect cells, with tag free.

HY-P705709

	*Janus kinase* 2/JAK2 Protein, Human (Inactive, V617F, sf9, StrepII, His, Avi)** Tyrosine-protein kinase JAK2; EC:2.7.10.2; Janus kinase 2 (JAK-2); JAK2	Human	Sf9 insect cells

HY-P706033

	*Janus kinase* 2/JAK2 Protein, Human (Inactive, sf9, His-GST)** Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	Human	Sf9 insect cells

HY-P706061

	*Janus kinase* 2/JAK2 Protein, Human (Active, sf9, His-GST)** Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	Human	Sf9 insect cells

HY-P706060

	*Janus kinase* 2/JAK2 Protein, Human (Inactive, V617F, sf9, His-GST)** Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	Human	Sf9 insect cells

HY-P706062

	*Janus kinase* 2/JAK2 Protein, Human (Active, JH2-JH1, sf9, His-GST)** Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	Human	Sf9 insect cells

HY-P7989

	*Janus kinase* 2/JAK2 Protein, Human (His)** 2 Publications Verification JAK2, Janus kinase 2	Human	E. coli
	Janus kinase 2/JAK2 Protein, Human (His) is a recombinant human JAK2 expressed in E. coli with a His tag at the N-terminus. JAK2 is a non-receptor tyrosine kinase.

HY-P705808

	*Janus kinase* 2/JAK2 Protein, Human (Inactive, Biotinylated, V617F, sf9, Avi)** JAK2, Janus kinase 2	Human	sf9 insect cells

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-169326S

JAK2-IN-11
JAK2-IN-11 (Example 6) is a *JAK2* kinase inhibitor with IC₅₀ ≤10 nM against JH2 BIND WT/V617F. JAK2-IN-11 has antitumor activity .

HY-126242S

Tyk2-IN-7

Tyk2-IN-7 is an orally active TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC₅₀ and K_i.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 can inhibit the IL-23 and IFN-α signaling pathways. Tyk2-IN-7 is commonly used in the study of inflammatory conditions such as colitis .

HY-W727879

Upadacitinib-15N,d2

1 Publications Verification

Upadacitinib- ¹⁵N,d₂ (ABT-494- ¹⁵N,d₂) is the deuterium-labeled Upadacitinib (HY-19569). Upadacitinib- ¹⁵N,d₂ (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib- ¹⁵N,d₂ (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib- ¹⁵N,d₂ (ABT-494) can be used for several autoimmune disorders research .

HY-10409S

Fedratinib-d9

Fedratinib-d₉ (TG-101348-d₉) is deuterium labeled Fedratinib. Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC₅₀s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research .

HY-103018S

Gusacitinib-d4

Gusacitinib-d₄ (ASN-002-d₄) is the deuterium labeled Gusacitinib (HY-103018). Gusacitinib (ASN-002) is an orally active dual SYK/JAK kinase inhibitor with IC₅₀ values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma .

Host:	Rabbit (5)
Reactivity:	Human (5) Rat (3) Mouse (5)
Application:	IHC-P (3) ICC/IF (3) IP (3) WB (5) FC (2) ELISA (1)
Isotype:	IgG (4) IgG/Kappa (1)
Conjugation:	Non-conjugated (5) Biotin (2)
Clonality:	Polyclonal (1) Monoclonal (3) Recombinant (2)
Modification:	Phosphorylated (1) Unmodified (3)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P80727

	JAK2 Antibody (YA330) 1 Publications Verification JAK2; Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	WB	Human, Mouse
	JAK2 Antibody (YA330) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to JAK2.

HY-P80727A

	JAK2 Antibody (YA330)(PBS only) JAK2; Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	WB	Human, Mouse
	JAK2 Antibody (YA330) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to JAK2.

HY-P80829

	Phospho-JAK2 (Tyr1007/1008) Antibody JAK2; Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	WB, IHC-P, ICC/IF, IP, FC	Human, Mouse, Rat
	Phospho-JAK2 (Tyr1007/1008) Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Phospho-JAK2 (Tyr1007/1008).

HY-P80829A

	Phospho-JAK2 (Tyr1007/1008) Antibody (YA6449) 1 Publications Verification JAK2; Tyrosine-protein kinase JAK2; Janus kinase 2; JAK-2	WB, IHC-P, ICC/IF, IP, FC	Human, Mouse, Rat
	Phospho-JAK2 (Tyr1007/1008) Antibody (YA6449) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-JAK2 (Tyr1007/1008).

HY-P86385

	JAK2 Antibody (YA6077) Tyrosine-protein kinase JAK2 (EC 2.7.10.2) (Janus kinase 2) (JAK-2)	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	JAK2 Antibody (YA6077) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to JAK2.